Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

NCT07359066 is registered in ClinicalTrials.gov with Shanghai SciBrunch Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07359066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07359066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Lead sponsor
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 8, 2026
Completion date
June 30, 2028
Enrollment
210 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, parp inhibitor